Collagen Matrix Inc., a leader in regenerative medicine, global manufacturer of collagen and mineral-based medical devices, and Linden Capital Partners portfolio company, announced today the appointment of Timothy J. Scannell to its board of directors. A seasoned and dynamic medical device leader, Mr. Scannell most recently served as President and Chief Operating Officer of Stryker.
Mr. Scannell brings 30 years of success and leadership from his broad experience at Stryker, one of the world’s leading medical technology companies. During his time as President and C.O.O., Mr. Scannell was responsible for all commercial businesses and regions globally for Stryker and delivered market-leading results. During his early career, Mr. Scannell led Stryker’s neurotechnology, spine, and medsurg businesses. Additionally, he served as general manager of Stryker’s biotech division. Mr. Scannell currently serves as Chair of Insulet Corporation’s board of directors. He also serves on the board of directors for Novocure.“Tim’s appointment represents a meaningful addition to our board, and I look forward to the strength and experience he will bring to the table” said Shawn McCarthy, President and Chief Executive Officer of Collagen Matrix, Inc. “He joins Collagen Matrix at an exciting time as we continue to accelerate our growth strategy and further our vision of improving patient lives through innovative regenerative devices. We are confident that Tim’s diversified leadership experience and proven track record will provide valuable perspective.” Mr. Scannell holds a Bachelor of Business Administration and a Master of Business Administration from the University of Notre Dame.
About Collagen Matrix, Inc.
Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration. Founded in 1997, Collagen Matrix is headquartered in Oakland, New Jersey and develops proprietary products that are sold to OEM customers on either a contract or private label basis across orthopedic, sports medicine, dental, and neurosurgery end markets. The company also offers partnership opportunities including distribution, contract product development, and contract manufacturing services. For more information, please visit www.collagenmatrix.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 200 total transactions. The firm has raised over $6 billion in limited partner commitments since inception. For more information, please visit www.lindenllc.com.
See open postions
Looking for a career with purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our careers page to learn more about what sets Regenity apart.
Regenity Capabilities Brochure
Download to learn more about Regenity’s contract development and manufacturing capabilities…
Collagen Matrix Inc. Unveils New Brand and Name as Regenity Biosciences
The rebrand supports the company’s position as material transformers in regenerative implant…
Vice President of R&D, Dan Ammon, inaugurated into the National Academy of Engineering (NAE)
We are excited to honor and celebrate our Vice President of R&D Dan Ammon and his recent…
Learn how to transform patient recovery through unique platforms and processes.